Safe, highly curative, short course, direct acting antiviral (DAA) therapies are now available to treat chronic hepatitis C. DAA therapy is freely available to all adults chronically infected with the hepatitis C virus (HCV) in Australia. However, since the introduction of funded DAA treatment, uptake has been suboptimal.
Researchers from University of Sydney and the Telethon Kids Institute with funding from WA Health are looking to engage GPs in a hepatitis C treatment registry study called PLATINUM C. The PLATINUM C Study aims to facilitate the prescribing of direct-acting antiviral (DAA) therapy and collect information on real-world outcomes of individuals treated for hepatitis C.
If your practice is interested in being part of the study, please email Jessica.email@example.com for further information.
For further information on Chronic Hepatitis C, please also visit the “Chronic Hep C” HealthPathway